Watson Pharmaceuticals, the third-biggest generics drugmaker, have changed their name to Actavis and set out their growth plans. The company initially revealed intentions to change their name last year, succeeding the acquisition of the Actavis Group. The company has begun a multi-year rebranding campaign that will guide the transition of their facilities, operations and commercial
Allergan have agreed to pay $25 per share in a bid to purchase Mountain View’s neurology group MAP Pharmaceuticals. The per share cash offer signifies a 60% premium over MAP’s closing stock price on January 22nd, and is equal to roughly $958 million. The merger agreement, which is expected to complete during the first or
Johnson & Johnson have announced an 8% rise in sales for their fourth quarter, aided by strong results from their pharmaceutical division. The group net income for the quarter was $2.57 billion, in comparison to $218 million in the fourth quarter of the previous year, when net income was affected by charges of $2.86 billion.
A £21 million fund will been made available to pay for rare orphan drugs that are not currently recommended by the Scotland’s regulatory watchdog, the Scottish Medicines Consortium (SMC). The fund will launch in March, and run until April 2014. It will help cover successful new Individual Patient Treatment Requests for drugs that target rare
Amgen has joined up with Bind Biosciences to develop a kinase inhibitor nanomedicine for treating a variety of solid tumours. The agreement provides the US biotech major with access to the technology at BIND, who has developed “a new class of highly selective targeted and programmable therapeutics,” which they call Accurins. The partners are planning
Sales of medication to treat ulcerative colitis in seven key markets are expected to double over the next decade, reaching $3.7 billion by 2021, according new research. The rapid growth will be largely driven by two premium-priced tumour necrosis factor-alpha (TNF-alpha) inhibitors – Abbott/Eisai’s Humira and Janssen/Merck/Mitsubishi Tanabe’s Simponi – and two novel therapies –
We would like to wish all our clients and candidates a very merry Christmas and a happy new year! Thank you for your business in 2012. We look forward to working with you in 2013! Only Medics will be closed from the afternoon of the 24th December 2012 until the 2nd January 2013. If you
A recent study has found that the use of antibiotics to treat persistent coughs (not caused by pneumonia) is ineffective. The European study involved 2,061 patients with acute lower-respiratory-tract infections where pneumonia was not suspected, and the patients were randomised to receive either amoxicillin or a placebo. The findings showed that neither the duration of
ACM Global Central Laboratory, the US-headquartered laboratory testing operation that raised its European profile in March 2009 by acquiring Pivotal Laboratories, have relocated their European laboratory to a bigger facility in York’s Hospital Fields Road. ACM Global confirmed that they have outgrown their prior facility in Aviator Court, York, which they have occupied since 1999.
GW Pharma has released mixed results for the year, with sales rising and profits decreasing, but the company continues to demonstrate potential in their R&D pipeline with inspiring data for a mid-stage, cannaboid-based diabetes drug. The organisation saw their sales for the year ending September 30, 2012, increase by £3.5 million to reach £33.1 million,